Nerve Pain Clinical Trials
Here are the 6 most popular medical studies for nerve pain
Local Anesthetic
Exparel for Craniofacial Pain
This trial will test whether a single dose of Exparel (a long-acting pain reliever) can provide pain relief for up to 72 hours after surgery, compared to a placebo. The study will be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion.
Surface Acoustic Wave Patch Device
PainShield SAW Patch Device for Trigeminal Neuralgia
This is a double blinded randomized control trial of a Surface Acoustic Wave Patch device for the treatment of Trigeminal Neuralgia. This will be a crossover study for the group that receives the sham device. Subjects will be monitored for subjective criteria of pain and quality of life, as well as objective measurement of analgesic usage.
Popular filter options for nerve pain trials
Diabetic Neuropathy Clinical Trials
View 19 Diabetic Neuropathy medical studies.
Procedure
Lidocaine Patch for Peripheral Neuropathy
This trial will compare a lidocaine patch to a placebo patch to see if the lidocaine patch helps reduce neuropathic pain. Measurements and a visual scale will track pain severity. The study will also assess a hybrid biomarker to distinguish between active and placebo treatments.
Cannabinoid
Nabilone for Diabetic Neuropathy
Neuropathic pain occurs as a result of damage or disease of the peripheral or central nervous system. Regardless of its cause, neuropathic pain (NeP) leads to a characteristic clinical picture characterized by ongoing pain with steady or dysesthetic pain, such as burning or aching, and paroxysmal pain such as shooting or stabbing. In conditions such as diabetic neuropathy, changes in the membrane-bound proteins that form ion channels may alter the electrical properties of the injured neuron, called remodeling. The net effect of membrane remodeling is greater excitability of neurons, leading to a tendency towards action potential generation and propagation in injured primary sensory neurons which occurs in the context of nerve injury and disease. Over the past decade, a new endogenous cannabinoid receptor-mediated system within the nervous system and upon immune-mediated cells has been described. The cannabinoid receptor system consists of two receptors, CB1 and CB2 receptors, as well as endogenously produced endocannabinoids which agonize these receptors. This is a multicenter trial amongst Western Canadian sites to compare the efficacy of nabilone versus placebo in treating patients with chronic neuropathic pain (NeP) due to diabetic peripheral neuropathy (DPN). A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate. All subjects will begin with nabilone therapy of 1 mg daily for a minimum of 4 days, with the dose of the study medication assessed and adjusted either upwards or downwards as needed to balance efficacy for pain control with tolerability of possible side effects. All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion of the study.
Bicifadine for Diabetic Neuropathy
To compare the efficacy of two dosages (600mg/day and 1200mg/day) of bicifadine SR with placebo for 14 weeks in reduction of chronic neuropathic patin (measured by a daily rating of pain intensity) associated with diabetic periperal neuropathy in adult outpatients. To compare the tolerability of two dosages of bicifadine SR with placebo in adult outpaitens treated for chronic neuropathic pain for 14 weeks associated with diabetic peripheral neuropathy.
Procedure
Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain
This trial is testing the effects of the study drug on neuropathic pain caused by chemotherapy. It will last 13 weeks and participants will be randomly assigned to either the study drug or placebo group.
Spinal Cord Injury Clinical Trials
View 15 Spinal Cord Injury medical studies.
Behavioural Intervention
Immersive Virtual Reality for Neuropathic Pain
The investigators hypothesize that SCI patients using immersive IVR training will show improved reduction of neuropathic pain that will outlast the training sessions and transfers into daily life.
Deep Brain Stimulation
DBS for Chronic Pain
This trial is testing a new way to provide deep brain stimulation (DBS) for people with chronic pain that has not been relieved by other treatments. DBS involves surgically placing a small device in the brain that sends electrical signals to specific areas. The goal of this trial is to find out whether DBS is more effective when it is turned on only when needed, rather than continuously.
Behavioural Intervention
Exercise Intervention for Neuropathic Pain After Spinal Cord Injury
This trial is studying how functional electrical stimulation (FES) can help people with spinal cord injuries by reducing pain, improving brain function, and increasing the size of the hippocampus.
Phase 3 Nerve Pain Clinical Trials
View 77 phase 3 nerve pain medical studies.
Behavioural Intervention
Immersive Virtual Reality for Neuropathic Pain
The investigators hypothesize that SCI patients using immersive IVR training will show improved reduction of neuropathic pain that will outlast the training sessions and transfers into daily life.
Cannabinoid
Nabilone for Diabetic Neuropathy
Neuropathic pain occurs as a result of damage or disease of the peripheral or central nervous system. Regardless of its cause, neuropathic pain (NeP) leads to a characteristic clinical picture characterized by ongoing pain with steady or dysesthetic pain, such as burning or aching, and paroxysmal pain such as shooting or stabbing. In conditions such as diabetic neuropathy, changes in the membrane-bound proteins that form ion channels may alter the electrical properties of the injured neuron, called remodeling. The net effect of membrane remodeling is greater excitability of neurons, leading to a tendency towards action potential generation and propagation in injured primary sensory neurons which occurs in the context of nerve injury and disease. Over the past decade, a new endogenous cannabinoid receptor-mediated system within the nervous system and upon immune-mediated cells has been described. The cannabinoid receptor system consists of two receptors, CB1 and CB2 receptors, as well as endogenously produced endocannabinoids which agonize these receptors. This is a multicenter trial amongst Western Canadian sites to compare the efficacy of nabilone versus placebo in treating patients with chronic neuropathic pain (NeP) due to diabetic peripheral neuropathy (DPN). A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate. All subjects will begin with nabilone therapy of 1 mg daily for a minimum of 4 days, with the dose of the study medication assessed and adjusted either upwards or downwards as needed to balance efficacy for pain control with tolerability of possible side effects. All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion of the study.
Nerve Pain Clinical Trials With No Placebo
View 77 nerve pain medical studies that do not have a placebo group.
Behavioural Intervention
Scrambler Therapy for Neuropathic Pain
This trial tests if a new therapy (ST) can reduce pain in people w/ corticobasal syndrome. Patients are randomly assigned TENS or ST, ECG electrodes placed, & treatment until relief is obtained. Results will show if ST is an effective pain relief option.
Behavioural Intervention
Immersive Virtual Reality for Neuropathic Pain
The investigators hypothesize that SCI patients using immersive IVR training will show improved reduction of neuropathic pain that will outlast the training sessions and transfers into daily life.
Deep Brain Stimulation
DBS for Chronic Pain
This trial is testing a new way to provide deep brain stimulation (DBS) for people with chronic pain that has not been relieved by other treatments. DBS involves surgically placing a small device in the brain that sends electrical signals to specific areas. The goal of this trial is to find out whether DBS is more effective when it is turned on only when needed, rather than continuously.
View More Nerve Pain Trials
See another 50 medical studies focused on nerve pain.
Frequently Asked Questions
Introduction to nerve pain
What are the top hospitals conducting nerve pain research?
Nerve pain, also known as neuropathic pain, can be debilitating and challenging to manage. However, leading hospitals across the United States are actively engaged in cutting-edge clinical trials to find innovative solutions for this condition. Stanford University, with its main campus located in Stanford and an additional center in Palo Alto, is paving the way with three ongoing nerve pain trials and a cumulative total of six past studies. Notably, their first recorded nerve pain trial dates back to 2016, demonstrating their commitment to tackling this complex issue.
In sunny Miami, the University of Miami has emerged as a significant player in nerve pain research. With three active clinical trials currently underway and four completed studies under their belt since initiating their first trial in 2017, they are dedicated to advancing understanding and treatment options for individuals experiencing nerve-related discomfort.
Meanwhile, all the way up north in Minneapolis at the University of Minnesota's renowned medical institution lies another hub of innovation when it comes to combating nerve pain. Having conducted five comprehensive trials thus far since embarking on their inaugural study in 2016 while simultaneously engaging with three active ones; they continue making strides towards improving patients' quality of life by addressing this often-agonizing ailment.
Boston's Massachusetts General Hospital rounds out our list but certainly not lacking when it comes to contributions against neuropathic agony. Since conducting its first groundbreaking trial back in2006,todaythey have three ongoing research investigations focused exclusively on tackling nerve pain while having garnered commendable completion recordsof six such tests throughout history.
These esteemed institutions illustrate that there is hope on the horizon for those grappling with unrelenting nerve pain - an affliction that affects countless individuals worldwide. Through pioneering research efforts taking place across these diverse locations nationwide,fresh insightsare continually being gained into this intricate condition.These invaluable initiatives bring us closer than ever before discovering novel treatments aimed at alleviating suffering endured by those affected by chronic neuropathy. With ongoing dedication and breakthroughs, these hospitals are paving the way towards a brighter, pain-free future for individuals grappling with nerve pain.
Which are the best cities for nerve pain clinical trials?
When it comes to nerve pain clinical trials, several cities in the United States stand out as hubs of research and development. Boston, Massachusetts leads the way with 11 active trials investigating treatments like Gabapentin and Qutenza. Houston, Texas follows closely behind with 10 ongoing studies focused on interventions such as Tetrodotoxin for injection. Miami, Florida also plays a significant role in nerve pain research with 8 active trials exploring options like Transcranial direct electrical stimulation. These cities, along with Chicago and New york City, offer individuals suffering from nerve pain opportunities to participate in cutting-edge clinical trials that may lead to improved management and relief of their symptoms.
Which are the top treatments for nerve pain being explored in clinical trials?
Exciting developments in clinical trials are shedding light on the top treatments being explored for nerve pain. [18F]FTC-146, a promising drug, is currently undergoing testing in two active trials dedicated to nerve pain. First introduced in 2018, it has already accumulated an impressive record of two all-time trials focused on tackling this challenging condition. Another notable contender is spinal cord stimulation, with two ongoing trials and a total of five historical studies addressing nerve pain since its introduction in 2014. Lastly, ketamine infusion shows promising potential as a treatment option for nerve pain and is currently being investigated in one active trial after making its first appearance on the scene in 2021. These innovative approaches offer hope for individuals struggling with debilitating nerve pain and may pave the way towards improved quality of life.
What are the most recent clinical trials for nerve pain?
Exciting developments in the field of nerve pain management have emerged from recent clinical trials. Among them, RTA 901, a groundbreaking treatment for nerve pain, has entered Phase 2 testing and shows promise in providing relief. Additionally, Gabapentin and THC (Dronabinol) have both progressed to Phase 3 and Phase 2 respectively as potential therapies for alleviating nerve pain. CBD/PEA is also being explored in Phases 1 and 2 studies with encouraging results thus far. Lastly, AFA-281 has initiated its Phase 1 trial targeting nerve pain management. These advancements signify significant progress towards improved treatments for individuals suffering from this debilitating condition.
What nerve pain clinical trials were recently completed?
Several clinical trials focusing on nerve pain have recently concluded, offering potential advancements in the management of this debilitating condition. In January 2022, Eli Lilly and Company successfully completed a trial investigating LY3526318's efficacy in addressing nerve pain. Preceding this, Lexicon Pharmaceuticals wrapped up their LX9211 trial in December 2020. Furthermore, November 2020 saw the completion of a trial for ETX-018810 conducted by Eliem Therapeutics (UK) Ltd., while Seema Capoor's Naloxone Hydrochloride 0.4 MG/ML study reached its conclusion in October 2020. These recent developments contribute to our understanding and treatment options for nerve pain, signifying progress towards improving patients' quality of life.